Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as Alzheimer's disease (AD). Injury to synapses and neurons and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles are considered the main morphological and neuropathological features of AD. Age, genetic and epigenetic factors, environmental stressors, and lifestyle contribute to the risk of AD onset and progression. These risk factors are associated with structural and functional changes in the brain, leading to cognitive decline. Biomarkers of AD reflect or cause specific changes in brain function, especially changes in pathways associated with neurotransmission, neuroinflammation, bioenergetics, apoptosis, and oxidative and nitrosative stress. Even in the initial stages, AD is associated with Aβ neurotoxicity, mitochondrial dysfunction, and tau neurotoxicity. The integrative amyloid-tau-mitochondrial hypothesis assumes that the primary cause of AD is the neurotoxicity of Aβ oligomers and tau oligomers, mitochondrial dysfunction, and their mutual synergy. For the development of new efficient AD drugs, targeting the elimination of neurotoxicity, mutual potentiation of effects, and unwanted protein interactions of risk factors and biomarkers (mainly Aβ oligomers, tau oligomers, and mitochondrial dysfunction) in the early stage of the disease seems promising.

Department of Psychiatry 1st Faculty of Medicine Charles University and General University Hospital Prague Ke Karlovu 11 120 00 Prague Czech Republic

Zobrazit více v PubMed

Pereira C.F., Santos A.E., Moreira P.I., Pereira A.C., Sousa F.J., Cardoso S.M., Cruz M.T. Is Alzheimer’s disease an inflammasomopathy? Ageing Res. Rev. 2019;56:100966. doi: 10.1016/j.arr.2019.100966. PubMed DOI

Wang J., Gu B.J., Masters C.L., Wang Y.J. A systemic view of Alzheimer disease—Insights from amyloid-β metabolism beyond the brain. Nat. Rev. Neurol. 2017;13:703. doi: 10.1038/nrneurol.2017.147. PubMed DOI

Goedert M., Klug A., Crowther R.A. Tau protein, the paired helical filament and Alzheimer’s disease. J. Alzheimer’s Dis. 2006;9:195–207. doi: 10.3233/JAD-2006-9S323. PubMed DOI

Moreira P.I., Carvalho C., Zhu X., Smith M.A., Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim. Biophys. Acta. 2010;1802:2–10. doi: 10.1016/j.bbadis.2009.10.006. PubMed DOI

Butterfield D.A., Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 2019;20:148–160. doi: 10.1038/s41583-019-0132-6. PubMed DOI PMC

Plascencia-Villa G., Perry G. Neuropathologic Changes Provide Insights into Key Mechanisms Related to Alzheimer Disease and Related Dementia. Am. J. Pathol. 2022;192:1340–1346. doi: 10.1016/j.ajpath.2022.07.002. PubMed DOI PMC

Hashimoto M., Rockenstein E., Crews L., Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromol. Med. 2003;4:21–36. doi: 10.1385/NMM:4:1-2:21. PubMed DOI

Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2012;2:700. doi: 10.1038/srep00700. PubMed DOI PMC

Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–539. doi: 10.1038/416535a. PubMed DOI

Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., Tapella L., Colombo L., Manzoni C., Borsello T., et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. USA. 2010;107:2295–2300. doi: 10.1073/pnas.0911829107. PubMed DOI PMC

Cline E.N., Bicca M.A., Viola K.L., Klein W.L. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimer’s Dis. 2018;64:S567–S610. doi: 10.3233/JAD-179941. PubMed DOI PMC

Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999;19:8876–8884. doi: 10.1523/JNEUROSCI.19-20-08876.1999. PubMed DOI PMC

Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101–112. doi: 10.1038/nrm2101. PubMed DOI

Griffiths J., Grant S.G.N. Synapse Pathology in Alzheimer’s Disease. Semin. Cell Dev. Biol. 2022. in press . PubMed DOI

Forloni G., Artuso V., La Vitola P., Balducci C. Oligomeropathies and pathogenesis of Alzheimer and Parkinson’s diseases. Mov. Disord. 2016;31:771–781. doi: 10.1002/mds.26624. PubMed DOI

Tasaki M., Ueda M., Ochiai S., Tanabe Y., Murata S., Misumi Y., Su Y., Sun X., Shinriki S., Jono H., et al. Transmission of circulating cell-free AA amyloid oligomers in exosomes vectors via a prion-like mechanism. Biochem. Biophys. Res. Commun. 2010;400:559–562. doi: 10.1016/j.bbrc.2010.08.101. PubMed DOI

Bloom G.S. Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505–508. doi: 10.1001/jamaneurol.2013.5847. PubMed DOI

Swardfager W., Lanctot K., Rothenburg L., Wong A., Cappell J., Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol. Psychiatry. 2010;68:930–941. doi: 10.1016/j.biopsych.2010.06.012. PubMed DOI

Liu Z., Zhou T., Ziegler A.C., Dimitrion P., Zuo L. Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxid. Med. Cell. Longev. 2017;2017:2525967. doi: 10.1155/2017/2525967. PubMed DOI PMC

Bhatia V., Sharma S. Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer’s disease. J. Neurol. Sci. 2021;421:117253. doi: 10.1016/j.jns.2020.117253. PubMed DOI

Demetrius L.A., Driver J. Alzheimer’s as a metabolic disease. Biogerontology. 2013;14:641–649. doi: 10.1007/s10522-013-9479-7. PubMed DOI

De la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem. Pharmacol. 2014;88:548–559. doi: 10.1016/j.bcp.2013.12.012. PubMed DOI PMC

Bonda D.J., Wang X., Lee H.G., Smith M.A., Perry G., Zhu X. Neuronal failure in Alzheimer’s disease: A view through the oxidative stress looking-glass. Neurosci. Bull. 2014;30:243–252. doi: 10.1007/s12264-013-1424-x. PubMed DOI PMC

Liu Z., Li T., Li P., Wei N., Zhao Z., Liang H., Ji X., Chen W., Xue M., Wei J. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer’s Disease. Oxid. Med. Cell. Longev. 2015;2015:352723. doi: 10.1155/2015/352723. PubMed DOI PMC

Eckert A., Schmitt K., Gotz J. Mitochondrial dysfunction—The beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimer’s Res. Ther. 2011;3:15. doi: 10.1186/alzrt74. PubMed DOI PMC

Jack C.R., Jr., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. PubMed DOI PMC

McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Jr., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. PubMed DOI PMC

Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimer’s Res. Ther. 2011;3:1. doi: 10.1186/alzrt59. PubMed DOI PMC

Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 2012;367:795–804. doi: 10.1056/NEJMoa1202753. PubMed DOI PMC

Hroudova J., Singh N., Fisar Z., Ghosh K.K. Progress in drug development for Alzheimer’s disease: An overview in relation to mitochondrial energy metabolism. Eur. J. Med. Chem. 2016;121:774–784. doi: 10.1016/j.ejmech.2016.03.084. PubMed DOI

Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spilker B.A., et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69:89–95. doi: 10.1067/mcp.2000.113989. PubMed DOI

Yu L., Boyle P.A., Segawa E., Leurgans S., Schneider J.A., Wilson R.S., Bennett D.A. Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology. 2015;29:335–343. doi: 10.1037/neu0000159. PubMed DOI PMC

Bennett D.A., Buchman A.S., Boyle P.A., Barnes L.L., Wilson R.S., Schneider J.A. Religious Orders Study and Rush Memory and Aging Project. J. Alzheimer’s Dis. 2018;64:S161–S189. doi: 10.3233/JAD-179939. PubMed DOI PMC

Van der Flier W.M., Scheltens P. Epidemiology and risk factors of dementia. J. Neurol. Neurosurg. Psychiatry. 2005;76((Suppl. S5)):v2–v7. doi: 10.1136/jnnp.2005.082867. PubMed DOI PMC

Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health. 1998;88:1337–1342. doi: 10.2105/AJPH.88.9.1337. PubMed DOI PMC

Andrews S.J., Fulton-Howard B., Goate A. Interpretation of risk loci from genome-wide association studies of Alzheimer’s disease. Lancet Neurol. 2020;19:326–335. doi: 10.1016/S1474-4422(19)30435-1. PubMed DOI PMC

Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-β but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010;67:122–131. doi: 10.1002/ana.21843. PubMed DOI PMC

Troutwine B.R., Hamid L., Lysaker C.R., Strope T.A., Wilkins H.M. Apolipoprotein E and Alzheimer’s disease. Acta Pharm. Sin. B. 2022;12:496–510. doi: 10.1016/j.apsb.2021.10.002. PubMed DOI PMC

Ramos-Cejudo J., Wisniewski T., Marmar C., Zetterberg H., Blennow K., de Leon M.J., Fossati S. Traumatic Brain Injury and Alzheimer’s Disease: The Cerebrovascular Link. EBioMedicine. 2018;28:21–30. doi: 10.1016/j.ebiom.2018.01.021. PubMed DOI PMC

Bellou V., Belbasis L., Tzoulaki I., Middleton L.T., Ioannidis J.P.A., Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses. Alzheimer’s Dement. 2017;13:406–418. doi: 10.1016/j.jalz.2016.07.152. PubMed DOI

Gaugler J., James B., Johnson T., Reimer J., Solis M., Weuve J., Buckley R.F., Hohman T.J. Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2022;18:700–789. doi: 10.1002/alz.12638. PubMed DOI

Ott A., Breteler M.M., van Harskamp F., Claus J.J., van der Cammen T.J., Grobbee D.E., Hofman A. Prevalence of Alzheimer’s disease and vascular dementia: Association with education. The Rotterdam study. BMJ. 1995;310:970–973. doi: 10.1136/bmj.310.6985.970. PubMed DOI PMC

Evans D.A., Hebert L.E., Beckett L.A., Scherr P.A., Albert M.S., Chown M.J., Pilgrim D.M., Taylor J.O. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch. Neurol. 1997;54:1399–1405. doi: 10.1001/archneur.1997.00550230066019. PubMed DOI

Flicker L. Modifiable lifestyle risk factors for Alzheimer’s disease. J. Alzheimer’s Dis. 2010;20:803–811. doi: 10.3233/JAD-2010-091624. PubMed DOI

Douros A., Santella C., Dell’Aniello S., Azoulay L., Renoux C., Suissa S., Brassard P. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study. J. Alzheimer’s Dis. 2021;81:329–338. doi: 10.3233/JAD-201534. PubMed DOI

Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349:151–154. doi: 10.1016/S0140-6736(96)09328-2. PubMed DOI

Luchsinger J.A., Reitz C., Honig L.S., Tang M.X., Shea S., Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–551. doi: 10.1212/01.wnl.0000172914.08967.dc. PubMed DOI PMC

Carlsson C.M. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease. J. Alzheimer’s Dis. 2010;20:711–722. doi: 10.3233/JAD-2010-100012. PubMed DOI PMC

Patel V.N., Chorawala M.R., Shah M.B., Shah K.C., Dave B.P., Shah M.P., Patel T.M. Emerging Pathophysiological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: An Old Wine in a New Bottle. J. Alzheimer’s Dis. Rep. 2022;6:349–357. doi: 10.3233/ADR-220021. PubMed DOI PMC

Yan X., Hu Y., Wang B., Wang S., Zhang X. Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease. Front. Neurosci. 2020;14:530219. doi: 10.3389/fnins.2020.530219. PubMed DOI PMC

Nelson P.T., Head E., Schmitt F.A., Davis P.R., Neltner J.H., Jicha G.A., Abner E.L., Smith C.D., Van Eldik L.J., Kryscio R.J., et al. Alzheimer’s disease is not “brain aging”: Neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121:571–587. doi: 10.1007/s00401-011-0826-y. PubMed DOI PMC

Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., Wallace D.C. Mitochondrial DNA deletions in human brain: Regional variability and increase with advanced age. Nat. Genet. 1992;2:324–329. doi: 10.1038/ng1292-324. PubMed DOI

Ojaimi J., Masters C.L., McLean C., Opeskin K., McKelvie P., Byrne E. Irregular distribution of cytochrome c oxidase protein subunits in aging and Alzheimer’s disease. Ann. Neurol. 1999;46:656–660. doi: 10.1002/1531-8249(199910)46:4<656::AID-ANA16>3.0.CO;2-Q. PubMed DOI

Weidling I., Swerdlow R.H. Mitochondrial Dysfunction and Stress Responses in Alzheimer’s Disease. Biology. 2019;8:39. doi: 10.3390/biology8020039. PubMed DOI PMC

Weidling I.W., Swerdlow R.H. Mitochondria in Alzheimer’s disease and their potential role in Alzheimer’s proteostasis. Exp. Neurol. 2020;330:113321. doi: 10.1016/j.expneurol.2020.113321. PubMed DOI PMC

Mielke M.M., Vemuri P., Rocca W.A. Clinical epidemiology of Alzheimer’s disease: Assessing sex and gender differences. Clin. Epidemiol. 2014;6:37–48. doi: 10.2147/CLEP.S37929. PubMed DOI PMC

Snyder H.M., Asthana S., Bain L., Brinton R., Craft S., Dubal D.B., Espeland M.A., Gatz M., Mielke M.M., Raber J., et al. Sex biology contributions to vulnerability to Alzheimer’s disease: A think tank convened by the Women’s Alzheimer’s Research Initiative. Alzheimer’s Dement. 2016;12:1186–1196. doi: 10.1016/j.jalz.2016.08.004. PubMed DOI PMC

Demetrius L.A., Eckert A., Grimm A. Sex differences in Alzheimer’s disease: Metabolic reprogramming and therapeutic intervention. Trends Endocrinol. Metab. 2021;32:963–979. doi: 10.1016/j.tem.2021.09.004. PubMed DOI

Breijyeh Z., Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020;25:5789. doi: 10.3390/molecules25245789. PubMed DOI PMC

Samieri C., Perier M.C., Gaye B., Proust-Lima C., Helmer C., Dartigues J.F., Berr C., Tzourio C., Empana J.P. Association of Cardiovascular Health Level in Older Age with Cognitive Decline and Incident Dementia. JAMA. 2018;320:657–664. doi: 10.1001/jama.2018.11499. PubMed DOI PMC

Ogino E., Manly J.J., Schupf N., Mayeux R., Gu Y. Current and past leisure time physical activity in relation to risk of Alzheimer’s disease in older adults. Alzheimer’s Dement. 2019;15:1603–1611. doi: 10.1016/j.jalz.2019.07.013. PubMed DOI PMC

Morris M.C., Tangney C.C., Wang Y., Sacks F.M., Bennett D.A., Aggarwal N.T. MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s Dement. 2015;11:1007–1014. doi: 10.1016/j.jalz.2014.11.009. PubMed DOI PMC

Sando S.B., Melquist S., Cannon A., Hutton M., Sletvold O., Saltvedt I., White L.R., Lydersen S., Aasly J. Risk-reducing effect of education in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2008;23:1156–1162. doi: 10.1002/gps.2043. PubMed DOI

Fann J.R., Ribe A.R., Pedersen H.S., Fenger-Gron M., Christensen J., Benros M.E., Vestergaard M. Long-term risk of dementia among people with traumatic brain injury in Denmark: A population-based observational cohort study. Lancet Psychiatry. 2018;5:424–431. doi: 10.1016/S2215-0366(18)30065-8. PubMed DOI

Plassman B.L., Havlik R.J., Steffens D.C., Helms M.J., Newman T.N., Drosdick D., Phillips C., Gau B.A., Welsh-Bohmer K.A., Burke J.R., et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000;55:1158–1166. doi: 10.1212/WNL.55.8.1158. PubMed DOI

Cherbuin N., Kim S., Anstey K.J. Dementia risk estimates associated with measures of depression: A systematic review and meta-analysis. BMJ Open. 2015;5:e008853. doi: 10.1136/bmjopen-2015-008853. PubMed DOI PMC

Terracciano A., Sutin A.R., An Y., O’Brien R.J., Ferrucci L., Zonderman A.B., Resnick S.M. Personality and risk of Alzheimer’s disease: New data and meta-analysis. Alzheimer’s Dement. 2014;10:179–186. doi: 10.1016/j.jalz.2013.03.002. PubMed DOI PMC

Avramopoulos D. Genetics of Alzheimer’s disease: Recent advances. Genome Med. 2009;1:34. doi: 10.1186/gm34. PubMed DOI PMC

Loy C.T., Schofield P.R., Turner A.M., Kwok J.B. Genetics of dementia. Lancet. 2014;383:828–840. doi: 10.1016/S0140-6736(13)60630-3. PubMed DOI

Ramos C., Aguillon D., Cordano C., Lopera F. Genetics of dementia: Insights from Latin America. Dement. Neuropsychol. 2020;14:223–236. doi: 10.1590/1980-57642020dn14-030004. PubMed DOI PMC

Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. PubMed DOI

Chen H., Chen F., Jiang Y., Zhang L., Hu G., Sun F., Zhang M., Ji Y., Chen Y., Che G., et al. A Review of ApoE4 Interference Targeting Mitophagy Molecular Pathways for Alzheimer’s Disease. Front. Aging Neurosci. 2022;14:881239. doi: 10.3389/fnagi.2022.881239. PubMed DOI PMC

Zhao N., Liu C.C., Van Ingelgom A.J., Martens Y.A., Linares C., Knight J.A., Painter M.M., Sullivan P.M., Bu G. Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron. 2017;96:115–129.e5. doi: 10.1016/j.neuron.2017.09.003. PubMed DOI PMC

Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–527. doi: 10.1038/nature24016. PubMed DOI PMC

Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet. 2009;41:1088–1093. doi: 10.1038/ng.440. PubMed DOI PMC

Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 2013;45:1452–1458. doi: 10.1038/ng.2802. PubMed DOI PMC

Jansen I.E., Savage J.E., Watanabe K., Bryois J., Williams D.M., Steinberg S., Sealock J., Karlsson I.K., Hagg S., Athanasiu L., et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 2019;51:404–413. doi: 10.1038/s41588-018-0311-9. PubMed DOI PMC

Marioni R.E., Harris S.E., Zhang Q., McRae A.F., Hagenaars S.P., Hill W.D., Davies G., Ritchie C.W., Gale C.R., Starr J.M., et al. GWAS on family history of Alzheimer’s disease. Transl. Psychiatry. 2018;8:99. doi: 10.1038/s41398-018-0150-6. PubMed DOI PMC

Kunkle B.W., Grenier-Boley B., Sims R., Bis J.C., Damotte V., Naj A.C., Boland A., Vronskaya M., van der Lee S.J., Amlie-Wolf A., et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat. Genet. 2019;51:414–430. doi: 10.1038/s41588-019-0358-2. PubMed DOI PMC

Murray M.E., Lowe V.J., Graff-Radford N.R., Liesinger A.M., Cannon A., Przybelski S.A., Rawal B., Parisi J.E., Petersen R.C., Kantarci K., et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain. 2015;138:1370–1381. doi: 10.1093/brain/awv050. PubMed DOI PMC

Bellenguez C., Charbonnier C., Grenier-Boley B., Quenez O., Le Guennec K., Nicolas G., Chauhan G., Wallon D., Rousseau S., Richard A.C., et al. Contribution to Alzheimer’s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol. Aging. 2017;59:220.e1–220.e9. doi: 10.1016/j.neurobiolaging.2017.07.001. PubMed DOI

Fu W.Y., Ip N.Y. The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction. Semin. Cell Dev. Biol. 2022 doi: 10.1016/j.semcdb.2022.07.011. in press . PubMed DOI

Nikolac Perkovic M., Videtic Paska A., Konjevod M., Kouter K., Svob Strac D., Nedic Erjavec G., Pivac N. Epigenetics of Alzheimer’s Disease. Biomolecules. 2021;11:195. doi: 10.3390/biom11020195. PubMed DOI PMC

Villa C., Stoccoro A. Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer’s Disease. Genes. 2022;13:1308. doi: 10.3390/genes13081308. PubMed DOI PMC

Gao X., Chen Q., Yao H., Tan J., Liu Z., Zhou Y., Zou Z. Epigenetics in Alzheimer’s Disease. Front. Aging Neurosci. 2022;14:911635. doi: 10.3389/fnagi.2022.911635. PubMed DOI PMC

Maity S., Farrell K., Navabpour S., Narayanan S.N., Jarome T.J. Epigenetic Mechanisms in Memory and Cognitive Decline Associated with Aging and Alzheimer’s Disease. Int. J. Mol. Sci. 2021;22:12280. doi: 10.3390/ijms222212280. PubMed DOI PMC

Pellegrini C., Pirazzini C., Sala C., Sambati L., Yusipov I., Kalyakulina A., Ravaioli F., Kwiatkowska K.M., Durso D.F., Ivanchenko M., et al. A Meta-Analysis of Brain DNA Methylation across Sex, Age, and Alzheimer’s Disease Points for Accelerated Epigenetic Aging in Neurodegeneration. Front. Aging Neurosci. 2021;13:639428. doi: 10.3389/fnagi.2021.639428. PubMed DOI PMC

Zhao Y., Jaber V., Alexandrov P.N., Vergallo A., Lista S., Hampel H., Lukiw W.J. microRNA-Based Biomarkers in Alzheimer’s Disease (AD) Front. Neurosci. 2020;14:585432. doi: 10.3389/fnins.2020.585432. PubMed DOI PMC

Arora T., Prashar V., Singh R., Barwal T.S., Changotra H., Sharma A., Parkash J. Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease. Mol. Neurobiol. 2022;59:6107–6124. doi: 10.1007/s12035-022-02950-z. PubMed DOI

Zetterberg H. Blood-based biomarkers for Alzheimer’s disease—An update. J. Neurosci. Methods. 2019;319:2–6. doi: 10.1016/j.jneumeth.2018.10.025. PubMed DOI

Marquez F., Yassa M.A. Neuroimaging Biomarkers for Alzheimer’s Disease. Mol. Neurodegener. 2019;14:21. doi: 10.1186/s13024-019-0325-5. PubMed DOI PMC

Jack C.R., Jr., Bennett D.A., Blennow K., Carrillo M.C., Feldman H.H., Frisoni G.B., Hampel H., Jagust W.J., Johnson K.A., Knopman D.S., et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547. doi: 10.1212/WNL.0000000000002923. PubMed DOI PMC

Hampel H., Cummings J., Blennow K., Gao P., Jack C.R., Jr., Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 2021;17:580–589. doi: 10.1038/s41582-021-00520-w. PubMed DOI

Baldeiras I., Santana I., Leitao M.J., Vieira D., Duro D., Mroczko B., Kornhuber J., Lewczuk P. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease. Alzheimer’s Res. Ther. 2019;11:2. doi: 10.1186/s13195-018-0456-x. PubMed DOI PMC

Leuzy A., Chiotis K., Lemoine L., Gillberg P.G., Almkvist O., Rodriguez-Vieitez E., Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol. Psychiatry. 2019;24:1112–1134. doi: 10.1038/s41380-018-0342-8. PubMed DOI PMC

Vlassenko A.G., Benzinger T.L., Morris J.C. PET amyloid-β imaging in preclinical Alzheimer’s disease. Biochim. Biophys. Acta. 2012;1822:370–379. doi: 10.1016/j.bbadis.2011.11.005. PubMed DOI PMC

Campese N., Palermo G., Del Gamba C., Beatino M.F., Galgani A., Belli E., Del Prete E., Della Vecchia A., Vergallo A., Siciliano G., et al. Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases. Expert Rev. Proteomics. 2021;18:27–48. doi: 10.1080/14789450.2021.1886929. PubMed DOI

Hampel H., Burger K., Teipel S.J., Bokde A.L., Zetterberg H., Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimer’s Dement. 2008;4:38–48. doi: 10.1016/j.jalz.2007.08.006. PubMed DOI

Zetterberg H. Applying fluid biomarkers to Alzheimer’s disease. Am. J. Physiol. Cell Physiol. 2017;313:C3–C10. doi: 10.1152/ajpcell.00007.2017. PubMed DOI PMC

Gordon B.A., Blazey T.M., Su Y., Hari-Raj A., Dincer A., Flores S., Christensen J., McDade E., Wang G., Xiong C., et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal study. Lancet Neurol. 2018;17:241–250. doi: 10.1016/S1474-4422(18)30028-0. PubMed DOI PMC

Murray M.E., Kouri N., Lin W.L., Jack C.R., Jr., Dickson D.W., Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer’s Res. Ther. 2014;6:1. doi: 10.1186/alzrt231. PubMed DOI PMC

Nakamura A., Kaneko N., Villemagne V.L., Kato T., Doecke J., Dore V., Fowler C., Li Q.X., Martins R., Rowe C., et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249–254. doi: 10.1038/nature25456. PubMed DOI

Li Y., Schindler S.E., Bollinger J.G., Ovod V., Mawuenyega K.G., Weiner M.W., Shaw L.M., Masters C.L., Fowler C.J., Trojanowski J.Q., et al. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology. 2022;98:e688–e699. doi: 10.1212/WNL.0000000000013211. PubMed DOI PMC

Leuzy A., Mattsson-Carlgren N., Palmqvist S., Janelidze S., Dage J.L., Hansson O. Blood-based biomarkers for Alzheimer’s disease. EMBO Mol. Med. 2022;14:e14408. doi: 10.15252/emmm.202114408. PubMed DOI PMC

Cummings J., Kinney J. Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation. Medicina. 2022;58:952. doi: 10.3390/medicina58070952. PubMed DOI PMC

Saint-Pol J., Gosselet F., Duban-Deweer S., Pottiez G., Karamanos Y. Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles. Cells. 2020;9:851. doi: 10.3390/cells9040851. PubMed DOI PMC

Park S.A., Jang Y.J., Kim M.K., Lee S.M., Moon S.Y. Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update. J. Clin. Neurol. 2022;18:401–409. doi: 10.3988/jcn.2022.18.4.401. PubMed DOI PMC

Carmona P., Molina M., Lopez-Tobar E., Toledano A. Vibrational spectroscopic analysis of peripheral blood plasma of patients with Alzheimer’s disease. Anal. Bioanal. Chem. 2015;407:7747–7756. doi: 10.1007/s00216-015-8940-7. PubMed DOI

O’Bryant S.E., Edwards M., Johnson L., Hall J., Villarreal A.E., Britton G.B., Quiceno M., Cullum C.M., Graff-Radford N.R. A blood screening test for Alzheimer’s disease. Alzheimer’s Dement. 2016;3:83–90. doi: 10.1016/j.dadm.2016.06.004. PubMed DOI PMC

Wang G., Zhou Y., Huang F.J., Tang H.D., Xu X.H., Liu J.J., Wang Y., Deng Y.L., Ren R.J., Xu W., et al. Plasma metabolite profiles of Alzheimer’s disease and mild cognitive impairment. J. Proteome Res. 2014;13:2649–2658. doi: 10.1021/pr5000895. PubMed DOI

Platenik J., Fisar Z., Buchal R., Jirak R., Kitzlerova E., Zverova M., Raboch J. GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer’s disease and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2014;50:83–93. doi: 10.1016/j.pnpbp.2013.12.001. PubMed DOI

Hampel H., Nistico R., Seyfried N.T., Levey A.I., Modeste E., Lemercier P., Baldacci F., Toschi N., Garaci F., Perry G., et al. Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence. Ageing Res. Rev. 2021;69:101346. doi: 10.1016/j.arr.2021.101346. PubMed DOI

Habartova L., Hrubesova K., Syslova K., Vondrousova J., Fisar Z., Jirak R., Raboch J., Setnicka V. Blood-based molecular signature of Alzheimer’s disease via spectroscopy and metabolomics. Clin. Biochem. 2019;72:58–63. doi: 10.1016/j.clinbiochem.2019.04.004. PubMed DOI

Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic. Biol. Med. 2007;43:658–677. doi: 10.1016/j.freeradbiomed.2007.05.037. PubMed DOI PMC

Fišar Z., Hroudová J., Hansiková H., Spáčilová J., Lelková P., Wenchich L., Jirák R., Zeman J., Martásek P., Raboch J. Mitochondrial respiration in the platelets of patients with Alzheimer’s disease. Curr. Alzheimer Res. 2016;13:930–941. doi: 10.2174/1567205013666160314150856. PubMed DOI

Fisar Z., Hansikova H., Krizova J., Jirak R., Kitzlerova E., Zverova M., Hroudova J., Wenchich L., Zeman J., Raboch J. Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer’s disease and depressive disorder. Mitochondrion. 2019;48:67–77. doi: 10.1016/j.mito.2019.07.013. PubMed DOI

Zheng C., Zhou X.W., Wang J.Z. The dual roles of cytokines in Alzheimer’s disease: Update on interleukins, TNF-α, TGF-β and IFN-γ. Transl. Neurodegener. 2016;5:7. doi: 10.1186/s40035-016-0054-4. PubMed DOI PMC

Mazzucchi S., Palermo G., Campese N., Galgani A., Della Vecchia A., Vergallo A., Siciliano G., Ceravolo R., Hampel H., Baldacci F. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Rev. Proteom. 2020;17:543–559. doi: 10.1080/14789450.2020.1831388. PubMed DOI

Alawode D.O.T., Fox N.C., Zetterberg H., Heslegrave A.J. Alzheimer’s Disease Biomarkers Revisited from the Amyloid Cascade Hypothesis Standpoint. Front. Neurosci. 2022;16:837390. doi: 10.3389/fnins.2022.837390. PubMed DOI PMC

Chatterjee P., Pedrini S., Stoops E., Goozee K., Villemagne V.L., Asih P.R., Verberk I.M.W., Dave P., Taddei K., Sohrabi H.R., et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl. Psychiatry. 2021;11:27. doi: 10.1038/s41398-020-01137-1. PubMed DOI PMC

Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 2013;368:117–127. doi: 10.1056/NEJMoa1211851. PubMed DOI PMC

Wolfe C.M., Fitz N.F., Nam K.N., Lefterov I., Koldamova R. The Role of APOE and TREM2 in Alzheimer’s Disease-Current Understanding and Perspectives. Int. J. Mol. Sci. 2018;20:81. doi: 10.3390/ijms20010081. PubMed DOI PMC

Lewczuk P., Riederer P., O’Bryant S.E., Verbeek M.M., Dubois B., Visser P.J., Jellinger K.A., Engelborghs S., Ramirez A., Parnetti L., et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry. 2018;19:244–328. doi: 10.1080/15622975.2017.1375556. PubMed DOI PMC

Jack C.R., Jr., Holtzman D.M. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80:1347–1358. doi: 10.1016/j.neuron.2013.12.003. PubMed DOI PMC

Leuzy A., Ashton N.J., Mattsson-Carlgren N., Dodich A., Boccardi M., Corre J., Drzezga A., Nordberg A., Ossenkoppele R., Zetterberg H., et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2121–2139. doi: 10.1007/s00259-021-05258-7. PubMed DOI PMC

Li R.X., Ma Y.H., Tan L., Yu J.T. Prospective biomarkers of Alzheimer’s disease: A systematic review and meta-analysis. Ageing Res. Rev. 2022;81:101699. doi: 10.1016/j.arr.2022.101699. PubMed DOI

Cullen N.C., Leuzy A., Janelidze S., Palmqvist S., Svenningsson A.L., Stomrud E., Dage J.L., Mattsson-Carlgren N., Hansson O. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat. Commun. 2021;12:3555. doi: 10.1038/s41467-021-23746-0. PubMed DOI PMC

Fisar Z., Jirak R., Zverova M., Setnicka V., Habartova L., Hroudova J., Vanickova Z., Raboch J. Plasma amyloid β levels and platelet mitochondrial respiration in patients with Alzheimer’s disease. Clin. Biochem. 2019;72:71–80. doi: 10.1016/j.clinbiochem.2019.04.003. PubMed DOI

Kitzlerova E., Fisar Z., Jirak R., Zverova M., Hroudova J., Benakova H., Raboch J. Plasma homocysteine in Alzheimer’s disease with or without co-morbid depressive symptoms. Neuro Endocrinol. Lett. 2014;35:42–49. PubMed

Zverova M., Fisar Z., Jirak R., Kitzlerova E., Hroudova J., Raboch J. Plasma cortisol in Alzheimer’s disease with or without depressive symptoms. Med. Sci. Monit. 2013;19:681–689. doi: 10.12659/MSM.889110. PubMed DOI PMC

Zverova M., Kitzlerova E., Fisar Z., Jirak R., Hroudova J., Benakova H., Lelkova P., Martasek P., Raboch J. Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease. Curr. Alzheimer Res. 2018;15:938–950. doi: 10.2174/1567205015666180601090533. PubMed DOI

Hansson O., Edelmayer R.M., Boxer A.L., Carrillo M.C., Mielke M.M., Rabinovici G.D., Salloway S., Sperling R., Zetterberg H., Teunissen C.E. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimer’s Dement. 2022:1–18. doi: 10.1002/alz.12756. PubMed DOI PMC

Jack C.R., Jr., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216. doi: 10.1016/S1474-4422(12)70291-0. PubMed DOI PMC

Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2013;12:357–367. doi: 10.1016/S1474-4422(13)70044-9. PubMed DOI

Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s Dement. 2012;8:1–13. doi: 10.1016/j.jalz.2011.10.007. PubMed DOI PMC

Thal D.R., Rub U., Orantes M., Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–1800. doi: 10.1212/WNL.58.12.1791. PubMed DOI

Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. doi: 10.1007/BF00308809. PubMed DOI

Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404. doi: 10.1007/s00401-006-0127-z. PubMed DOI PMC

Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–486. doi: 10.1212/WNL.41.4.479. PubMed DOI

Alafuzoff I., Arzberger T., Al-Sarraj S., Bodi I., Bogdanovic N., Braak H., Bugiani O., Del-Tredici K., Ferrer I., Gelpi E., et al. Staging of neurofibrillary pathology in Alzheimer’s disease: A study of the BrainNet Europe Consortium. Brain Pathol. 2008;18:484–496. doi: 10.1111/j.1750-3639.2008.00147.x. PubMed DOI PMC

Tissot C., Therriault J., Kunach P., Benedet A.L., Pascoal T.A., Ashton N.J., Karikari T.K., Servaes S., Lussier F.Z., Chamoun M., et al. Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET. EBioMedicine. 2022;76:103837. doi: 10.1016/j.ebiom.2022.103837. PubMed DOI PMC

Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Jr., Kaye J., Montine T.J., et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:280–292. doi: 10.1016/j.jalz.2011.03.003. PubMed DOI PMC

Long J.M., Holtzman D.M. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179:312–339. doi: 10.1016/j.cell.2019.09.001. PubMed DOI PMC

Lowe V.J., Lundt E.S., Albertson S.M., Przybelski S.A., Senjem M.L., Parisi J.E., Kantarci K., Boeve B., Jones D.T., Knopman D., et al. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer’s Dement. 2019;15:927–939. doi: 10.1016/j.jalz.2019.03.016. PubMed DOI PMC

Sato C., Barthelemy N.R., Mawuenyega K.G., Patterson B.W., Gordon B.A., Jockel-Balsarotti J., Sullivan M., Crisp M.J., Kasten T., Kirmess K.M., et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97:1284–1298.e7. doi: 10.1016/j.neuron.2018.02.015. PubMed DOI PMC

Di J., Cohen L.S., Corbo C.P., Phillips G.R., El Idrissi A., Alonso A.D. Abnormal tau induces cognitive impairment through two different mechanisms: Synaptic dysfunction and neuronal loss. Sci. Rep. 2016;6:20833. doi: 10.1038/srep20833. PubMed DOI PMC

Barthelemy N.R., Li Y., Joseph-Mathurin N., Gordon B.A., Hassenstab J., Benzinger T.L.S., Buckles V., Fagan A.M., Perrin R.J., Goate A.M., et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat. Med. 2020;26:398–407. doi: 10.1038/s41591-020-0781-z. PubMed DOI PMC

Koss D.J., Jones G., Cranston A., Gardner H., Kanaan N.M., Platt B. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline. Acta Neuropathol. 2016;132:875–895. doi: 10.1007/s00401-016-1632-3. PubMed DOI PMC

Pimplikar S.W., Nixon R.A., Robakis N.K., Shen J., Tsai L.H. Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J. Neurosci. 2010;30:14946–14954. doi: 10.1523/JNEUROSCI.4305-10.2010. PubMed DOI PMC

Herrup K. Reimagining Alzheimer’s disease—An age-based hypothesis. J. Neurosci. 2010;30:16755–16762. doi: 10.1523/JNEUROSCI.4521-10.2010. PubMed DOI PMC

Wareham L.K., Liddelow S.A., Temple S., Benowitz L.I., Di Polo A., Wellington C., Goldberg J.L., He Z., Duan X., Bu G., et al. Solving neurodegeneration: Common mechanisms and strategies for new treatments. Mol. Neurodegener. 2022;17:23. doi: 10.1186/s13024-022-00524-0. PubMed DOI PMC

Liu P.P., Xie Y., Meng X.Y., Kang J.S. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct. Target. Ther. 2019;4:29. doi: 10.1038/s41392-019-0063-8. PubMed DOI PMC

Karran E., De Strooper B. The amyloid cascade hypothesis: Are we poised for success or failure? J. Neurochem. 2016;139((Suppl. S2)):237–252. doi: 10.1111/jnc.13632. PubMed DOI

Hardy J.A., Higgins G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science. 1992;256:184–185. doi: 10.1126/science.1566067. PubMed DOI

Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991;12:383–388. doi: 10.1016/0165-6147(91)90609-V. PubMed DOI

Walsh D.M., Selkoe D.J. Aβ oligomers—A decade of discovery. J. Neurochem. 2007;101:1172–1184. doi: 10.1111/j.1471-4159.2006.04426.x. PubMed DOI

Yang T., Li S., Xu H., Walsh D.M., Selkoe D.J. Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J. Neurosci. 2017;37:152–163. doi: 10.1523/JNEUROSCI.1698-16.2016. PubMed DOI PMC

Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 2016;8:595–608. doi: 10.15252/emmm.201606210. PubMed DOI PMC

Jellinger K.A. Basic mechanisms of neurodegeneration: A critical update. J. Cell. Mol. Med. 2010;14:457–487. doi: 10.1111/j.1582-4934.2010.01010.x. PubMed DOI PMC

Harris L.D., Jasem S., Licchesi J.D.F. The Ubiquitin System in Alzheimer’s Disease. Adv. Exp. Med. Biol. 2020;1233:195–221. doi: 10.1007/978-3-030-38266-7_8. PubMed DOI

Richard R., Mousa S. Necroptosis in Alzheimer’s disease: Potential therapeutic target. Biomed. Pharmacother. 2022;152:113203. doi: 10.1016/j.biopha.2022.113203. PubMed DOI

Mangalmurti A., Lukens J.R. How neurons die in Alzheimer’s disease: Implications for neuroinflammation. Curr. Opin. Neurobiol. 2022;75:102575. doi: 10.1016/j.conb.2022.102575. PubMed DOI PMC

Musiek E.S., Holtzman D.M. Three dimensions of the amyloid hypothesis: Time, space and ‘wingmen’. Nat. Neurosci. 2015;18:800–806. doi: 10.1038/nn.4018. PubMed DOI PMC

Folch J., Ettcheto M., Petrov D., Abad S., Pedros I., Marin M., Olloquequi J., Camins A. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Neurol. Engl. Ed. 2018;33:47–58. doi: 10.1016/j.nrleng.2015.03.019. PubMed DOI

De Strooper B., Karran E. The Cellular Phase of Alzheimer’s Disease. Cell. 2016;164:603–615. doi: 10.1016/j.cell.2015.12.056. PubMed DOI

Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012;2:a006270. doi: 10.1101/cshperspect.a006270. PubMed DOI PMC

Delport A., Hewer R. The amyloid precursor protein: A converging point in Alzheimer’s disease. Mol. Neurobiol. 2022;59:4501–4516. doi: 10.1007/s12035-022-02863-x. PubMed DOI

Li X., Uemura K., Hashimoto T., Nasser-Ghodsi N., Arimon M., Lill C.M., Palazzolo I., Krainc D., Hyman B.T., Berezovska O. Neuronal activity and secreted amyloid β lead to altered amyloid β precursor protein and presenilin 1 interactions. Neurobiol. Dis. 2013;50:127–134. doi: 10.1016/j.nbd.2012.10.002. PubMed DOI PMC

Chang Y.J., Chen Y.R. The coexistence of an equal amount of Alzheimer’s amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway. FEBS J. 2014;281:2674–2687. doi: 10.1111/febs.12813. PubMed DOI

Verma M., Vats A., Taneja V. Toxic species in amyloid disorders: Oligomers or mature fibrils. Ann. Indian Acad. Neurol. 2015;18:138–145. doi: 10.4103/0972-2327.144284. PubMed DOI PMC

Chen G.F., Xu T.H., Yan Y., Zhou Y.R., Jiang Y., Melcher K., Xu H.E. Amyloid β: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017;38:1205–1235. doi: 10.1038/aps.2017.28. PubMed DOI PMC

Jarosz-Griffiths H.H., Noble E., Rushworth J.V., Hooper N.M. Amyloid-β Receptors: The Good, the Bad, and the Prion Protein. J. Biol. Chem. 2016;291:3174–3183. doi: 10.1074/jbc.R115.702704. PubMed DOI PMC

Canale C., Seghezza S., Vilasi S., Carrotta R., Bulone D., Diaspro A., San Biagio P.L., Dante S. Different effects of Alzheimer’s peptide Aβ(1–40) oligomers and fibrils on supported lipid membranes. Biophys. Chem. 2013;182:23–29. doi: 10.1016/j.bpc.2013.07.010. PubMed DOI

Evangelisti E., Cascella R., Becatti M., Marrazza G., Dobson C.M., Chiti F., Stefani M., Cecchi C. Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. Sci. Rep. 2016;6:32721. doi: 10.1038/srep32721. PubMed DOI PMC

Kayed R., Lasagna-Reeves C.A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimer’s Dis. 2013;33((Suppl. S1)):S67–S78. doi: 10.3233/JAD-2012-129001. PubMed DOI

Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837–842. doi: 10.1038/nm1782. PubMed DOI PMC

Muller-Schiffmann A., Herring A., Abdel-Hafiz L., Chepkova A.N., Schable S., Wedel D., Horn A.H., Sticht H., de Souza Silva M.A., Gottmann K., et al. Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain. 2016;139:509–525. doi: 10.1093/brain/awv355. PubMed DOI

Narayan P., Meehan S., Carver J.A., Wilson M.R., Dobson C.M., Klenerman D. Amyloid-β oligomers are sequestered by both intracellular and extracellular chaperones. Biochemistry. 2012;51:9270–9276. doi: 10.1021/bi301277k. PubMed DOI PMC

Overk C.R., Masliah E. Toward a unified therapeutics approach targeting putative amyloid-β oligomer receptors. Proc. Natl. Acad. Sci. USA. 2014;111:13680–13681. doi: 10.1073/pnas.1414554111. PubMed DOI PMC

Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A., McKhann G., Funatsu Y., Nakamichi N., et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction. Proc. Natl. Acad. Sci. USA. 2009;106:20021–20026. doi: 10.1073/pnas.0905686106. PubMed DOI PMC

Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907–913. doi: 10.1038/nm890. PubMed DOI

Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L., Liu R., Wang J.Z., Zhou X.W. Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis. 2013;4:e673. doi: 10.1038/cddis.2013.180. PubMed DOI PMC

Batkulwar K., Godbole R., Banarjee R., Kassaar O., Williams R.J., Kulkarni M.J. Advanced Glycation End Products Modulate Amyloidogenic APP Processing and Tau Phosphorylation: A Mechanistic Link between Glycation and the Development of Alzheimer’s Disease. ACS Chem. Neurosci. 2018;9:988–1000. doi: 10.1021/acschemneuro.7b00410. PubMed DOI

Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Investig. 2012;122:1377–1392. doi: 10.1172/JCI58642. PubMed DOI PMC

Hampel H., Hardy J., Blennow K., Chen C., Perry G., Kim S.H., Villemagne V.L., Aisen P., Vendruscolo M., Iwatsubo T., et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol. Psychiatry. 2021;26:5481–5503. doi: 10.1038/s41380-021-01249-0. PubMed DOI PMC

Zerbinatti C.V., Bu G. LRP and Alzheimer’s disease. Rev. Neurosci. 2005;16:123–135. doi: 10.1515/REVNEURO.2005.16.2.123. PubMed DOI

Shinohara M., Tachibana M., Kanekiyo T., Bu G. Role of LRP1 in the pathogenesis of Alzheimer’s disease: Evidence from clinical and preclinical studies. J. Lipid Res. 2017;58:1267–1281. doi: 10.1194/jlr.R075796. PubMed DOI PMC

Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., et al. Clearance of Alzheimer’s amyloid-β(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Investig. 2000;106:1489–1499. doi: 10.1172/JCI10498. PubMed DOI PMC

Viola K.L., Klein W.L. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183–206. doi: 10.1007/s00401-015-1386-3. PubMed DOI PMC

Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1986;83:4044–4048. doi: 10.1073/pnas.83.11.4044. PubMed DOI PMC

Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: Implications for Alzheimer’s disease. Neurochem. Int. 2011;58:458–471. doi: 10.1016/j.neuint.2010.12.023. PubMed DOI

Arnsten A.F.T., Datta D., Del Tredici K., Braak H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimer’s Dement. 2021;17:115–124. doi: 10.1002/alz.12192. PubMed DOI PMC

Kametani F., Hasegawa M. Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer’s Disease. Front. Neurosci. 2018;12:25. doi: 10.3389/fnins.2018.00025. PubMed DOI PMC

Ward S.M., Himmelstein D.S., Lancia J.K., Binder L.I. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem. Soc. Trans. 2012;40:667–671. doi: 10.1042/BST20120134. PubMed DOI PMC

Cardenas-Aguayo Mdel C., Gomez-Virgilio L., DeRosa S., Meraz-Rios M.A. The role of tau oligomers in the onset of Alzheimer’s disease neuropathology. ACS Chem. Neurosci. 2014;5:1178–1191. doi: 10.1021/cn500148z. PubMed DOI

Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007;27:3650–3662. doi: 10.1523/JNEUROSCI.0587-07.2007. PubMed DOI PMC

Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Clos A.L., Jackson G.R., Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 2011;6:39. doi: 10.1186/1750-1326-6-39. PubMed DOI PMC

Lasagna-Reeves C.A., Sengupta U., Castillo-Carranza D., Gerson J.E., Guerrero-Munoz M., Troncoso J.C., Jackson G.R., Kayed R. The formation of tau pore-like structures is prevalent and cell specific: Possible implications for the disease phenotypes. Acta Neuropathol. Commun. 2014;2:56. doi: 10.1186/2051-5960-2-56. PubMed DOI PMC

Gerson J.E., Sengupta U., Lasagna-Reeves C.A., Guerrero-Munoz M.J., Troncoso J., Kayed R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2014;2:73. doi: 10.1186/2051-5960-2-73. PubMed DOI PMC

Hernandez F., Lucas J.J., Avila J. GSK3 and tau: Two convergence points in Alzheimer’s disease. J. Alzheimer’s Dis. 2013;33((Suppl. S1)):S141–S144. doi: 10.3233/JAD-2012-129025. PubMed DOI

Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J. Neurochem. 2008;104:1433–1439. doi: 10.1111/j.1471-4159.2007.05194.x. PubMed DOI PMC

Muralidar S., Ambi S.V., Sekaran S., Thirumalai D., Palaniappan B. Role of tau protein in Alzheimer’s disease: The prime pathological player. Int. J. Biol. Macromol. 2020;163:1599–1617. doi: 10.1016/j.ijbiomac.2020.07.327. PubMed DOI

Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009;15:112–119. doi: 10.1016/j.molmed.2009.01.003. PubMed DOI

Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimer’s Dis. 2013;33((Suppl. S1)):S123–S139. doi: 10.3233/JAD-2012-129031. PubMed DOI

Soeda Y., Takashima A. New Insights Into Drug Discovery Targeting Tau Protein. Front. Mol. Neurosci. 2020;13:590896. doi: 10.3389/fnmol.2020.590896. PubMed DOI PMC

Zhang H., Cao Y., Ma L., Wei Y., Li H. Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease. Front. Cell Dev. Biol. 2021;9:707268. doi: 10.3389/fcell.2021.707268. PubMed DOI PMC

Blurton-Jones M., Laferla F.M. Pathways by which Aβ facilitates tau pathology. Curr. Alzheimer Res. 2006;3:437–448. doi: 10.2174/156720506779025242. PubMed DOI

Pascoal T.A., Mathotaarachchi S., Shin M., Benedet A.L., Mohades S., Wang S., Beaudry T., Kang M.S., Soucy J.P., Labbe A., et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimer’s Dement. 2017;13:644–653. doi: 10.1016/j.jalz.2016.11.005. PubMed DOI

Um J.W., Kaufman A.C., Kostylev M., Heiss J.K., Stagi M., Takahashi H., Kerrisk M.E., Vortmeyer A., Wisniewski T., Koleske A.J., et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron. 2013;79:887–902. doi: 10.1016/j.neuron.2013.06.036. PubMed DOI PMC

Zhao Y., Kuca K., Wu W., Wang X., Nepovimova E., Musilek K., Wu Q. Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimer’s Dement. 2022;18:152–158. doi: 10.1002/alz.12370. PubMed DOI

Swerdlow R.H. Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease. J. Alzheimer’s Dis. 2018;62:1403–1416. doi: 10.3233/JAD-170585. PubMed DOI PMC

Swerdlow R.H. The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer’s disease. Int. Rev. Neurobiol. 2020;154:207–233. doi: 10.1016/bs.irn.2020.01.008. PubMed DOI PMC

Torres A.K., Jara C., Park-Kang H.S., Polanco C.M., Tapia D., Alarcon F., de la Pena A., Llanquinao J., Vargas-Mardones G., Indo J.A., et al. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer’s Disease. J. Alzheimer’s Dis. 2021;84:1391–1414. doi: 10.3233/JAD-215139. PubMed DOI

Vance J.E. MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond. Biochim. Biophys. Acta. 2014;1841:595–609. doi: 10.1016/j.bbalip.2013.11.014. PubMed DOI

Giacomello M., Pellegrini L. The coming of age of the mitochondria-ER contact: A matter of thickness. Cell Death Differ. 2016;23:1417–1427. doi: 10.1038/cdd.2016.52. PubMed DOI PMC

Area-Gomez E., de Groof A.J., Boldogh I., Bird T.D., Gibson G.E., Koehler C.M., Yu W.H., Duff K.E., Yaffe M.P., Pon L.A., et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am. J. Pathol. 2009;175:1810–1816. doi: 10.2353/ajpath.2009.090219. PubMed DOI PMC

Del Prete D., Suski J.M., Oules B., Debayle D., Gay A.S., Lacas-Gervais S., Bussiere R., Bauer C., Pinton P., Paterlini-Brechot P., et al. Localization and Processing of the Amyloid-β Protein Precursor in Mitochondria-Associated Membranes. J. Alzheimer’s Dis. 2017;55:1549–1570. doi: 10.3233/JAD-160953. PubMed DOI PMC

Schon E.A., Area-Gomez E. Mitochondria-associated ER membranes in Alzheimer disease. Mol. Cell. Neurosci. 2013;55:26–36. doi: 10.1016/j.mcn.2012.07.011. PubMed DOI

Eysert F., Kinoshita P.F., Mary A., Vaillant-Beuchot L., Checler F., Chami M. Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimer’s Disease. Int. J. Mol. Sci. 2020;21:9521. doi: 10.3390/ijms21249521. PubMed DOI PMC

Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529–535. doi: 10.1038/nature08983. PubMed DOI PMC

Payne B.A., Chinnery P.F. Mitochondrial dysfunction in aging: Much progress but many unresolved questions. Biochim. Biophys. Acta. 2015;1847:1347–1353. doi: 10.1016/j.bbabio.2015.05.022. PubMed DOI PMC

Cenini G., Voos W. Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update. Front. Pharmacol. 2019;10:902. doi: 10.3389/fphar.2019.00902. PubMed DOI PMC

Swerdlow R.H., Koppel S., Weidling I., Hayley C., Ji Y., Wilkins H.M. Mitochondria, Cybrids, Aging, and Alzheimer’s Disease. Prog. Mol. Biol. Transl. Sci. 2017;146:259–302. doi: 10.1016/bs.pmbts.2016.12.017. PubMed DOI PMC

Jia K., Du H. Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimer’s Disease. Cells. 2021;10:649. doi: 10.3390/cells10030649. PubMed DOI PMC

Hroudova J., Singh N., Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer’s disease. BioMed Res. Int. 2014;2014:175062. doi: 10.1155/2014/175062. PubMed DOI PMC

Paradies G., Paradies V., Ruggiero F.M., Petrosillo G. Changes in the mitochondrial permeability transition pore in aging and age-associated diseases. Mech. Ageing Dev. 2013;134:1–9. doi: 10.1016/j.mad.2012.12.006. PubMed DOI

Reiss A.B., Ahmed S., Dayaramani C., Glass A.D., Gomolin I.H., Pinkhasov A., Stecker M.M., Wisniewski T., De Leon J. The role of mitochondrial dysfunction in Alzheimer’s disease: A potential pathway to treatment. Exp. Gerontol. 2022;164:111828. doi: 10.1016/j.exger.2022.111828. PubMed DOI

Blagov A.V., Grechko A.V., Nikiforov N.G., Borisov E.E., Sadykhov N.K., Orekhov A.N. Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer’s Disease. Int. J. Mol. Sci. 2022;23:6954. doi: 10.3390/ijms23136954. PubMed DOI PMC

Hroudova J., Fisar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin. Neurosci. 2011;65:130–141. doi: 10.1111/j.1440-1819.2010.02178.x. PubMed DOI

Bernardi P. Why F-ATP Synthase Remains a Strong Candidate as the Mitochondrial Permeability Transition Pore. Front. Physiol. 2018;9:1543. doi: 10.3389/fphys.2018.01543. PubMed DOI PMC

Amadoro G., Corsetti V., Atlante A., Florenzano F., Capsoni S., Bussani R., Mercanti D., Calissano P. Interaction between NH2-tau fragment and Aβ in Alzheimer’s disease mitochondria contributes to the synaptic deterioration. Neurobiol. Aging. 2012;33:833.e1–833.e25. doi: 10.1016/j.neurobiolaging.2011.08.001. PubMed DOI

John A., Reddy P.H. Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid β, P-tau and mitochondria. Ageing Res. Rev. 2021;65:101208. doi: 10.1016/j.arr.2020.101208. PubMed DOI PMC

Kocahan S., Dogan Z. Mechanisms of Alzheimer’s Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clin. Psychopharmacol. Neurosci. 2017;15:1–8. doi: 10.9758/cpn.2017.15.1.1. PubMed DOI PMC

Neill D. Alzheimer’s disease: Maladaptive synaptoplasticity hypothesis. Neurodegeneration. 1995;4:217–232. doi: 10.1006/neur.1995.0027. PubMed DOI

Mesulam M.M. Neuroplasticity failure in Alzheimer’s disease: Bridging the gap between plaques and tangles. Neuron. 1999;24:521–529. doi: 10.1016/S0896-6273(00)81109-5. PubMed DOI

Citri A., Malenka R.C. Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008;33:18–41. doi: 10.1038/sj.npp.1301559. PubMed DOI

Bello-Medina P.C., Gonzalez-Franco D.A., Vargas-Rodriguez I., Diaz-Cintra S. Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease. Neurol. Engl. Ed. 2022;37:682–690. doi: 10.1016/j.nrleng.2019.06.008. PubMed DOI

Merceron-Martinez D., Ibaceta-Gonzalez C., Salazar C., Almaguer-Melian W., Bergado-Rosado J.A., Palacios A.G. Alzheimer’s Disease, Neural Plasticity, and Functional Recovery. J. Alzheimer’s Dis. 2021;82:S37–S50. doi: 10.3233/JAD-201178. PubMed DOI

Teter B., Ashford J.W. Neuroplasticity in Alzheimer’s disease. J. Neurosci. Res. 2002;70:402–437. doi: 10.1002/jnr.10441. PubMed DOI

Bailey C.H., Giustetto M., Huang Y.Y., Hawkins R.D., Kandel E.R. Is heterosynaptic modulation essential for stabilizing Hebbian plasticity and memory? Nat. Rev. Neurosci. 2000;1:11–20. doi: 10.1038/35036191. PubMed DOI

Abraham W.C. Metaplasticity: Tuning synapses and networks for plasticity. Nat. Rev. Neurosci. 2008;9:387. doi: 10.1038/nrn2356. PubMed DOI

Jang S.S., Chung H.J. Emerging Link between Alzheimer’s Disease and Homeostatic Synaptic Plasticity. Neural Plast. 2016;2016:7969272. doi: 10.1155/2016/7969272. PubMed DOI PMC

Li S., Selkoe D.J. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain. J. Neurochem. 2020;154:583–597. doi: 10.1111/jnc.15007. PubMed DOI PMC

Walsh C., Drinkenburg W.H., Ahnaou A. Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer’s disease. Neurosci. Biobehav. Rev. 2017;73:340–358. doi: 10.1016/j.neubiorev.2016.12.020. PubMed DOI

Long H.Z., Zhou Z.W., Cheng Y., Luo H.Y., Li F.J., Xu S.G., Gao L.C. The Role of Microglia in Alzheimer’s Disease from the Perspective of Immune Inflammation and Iron Metabolism. Front. Aging Neurosci. 2022;14:888989. doi: 10.3389/fnagi.2022.888989. PubMed DOI PMC

Vainchtein I.D., Molofsky A.V. Astrocytes and Microglia: In Sickness and in Health. Trends Neurosci. 2020;43:144–154. doi: 10.1016/j.tins.2020.01.003. PubMed DOI PMC

Voet S., Srinivasan S., Lamkanfi M., van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol. Med. 2019;11:e10248. doi: 10.15252/emmm.201810248. PubMed DOI PMC

Hylén U., Eklund D., Humble M., Bartoszek J., Sarndahl E., Bejerot S. Increased inflammasome activity in markedly ill psychiatric patients: An explorative study. J. Neuroimmunol. 2020;339:577119. doi: 10.1016/j.jneuroim.2019.577119. PubMed DOI

Weng S., Lai Q.L., Wang J., Zhuang L., Cheng L., Mo Y., Liu L., Zhao Z., Zhang Y., Qiao S. The Role of Exosomes as Mediators of Neuroinflammation in the Pathogenesis and Treatment of Alzheimer’s Disease. Front. Aging Neurosci. 2022;14:899944. doi: 10.3389/fnagi.2022.899944. PubMed DOI PMC

Zhao Y., Liu B., Wang J., Xu L., Yu S., Fu J., Yan X., Su J. Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease. Biomedicines. 2022;10:1800. doi: 10.3390/biomedicines10081800. PubMed DOI PMC

Noonin C., Thongboonkerd V. Exosome-inflammasome crosstalk and their roles in inflammatory responses. Theranostics. 2021;11:4436–4451. doi: 10.7150/thno.54004. PubMed DOI PMC

Efthymiou A.G., Goate A.M. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 2017;12:43. doi: 10.1186/s13024-017-0184-x. PubMed DOI PMC

Kinney J.W., Bemiller S.M., Murtishaw A.S., Leisgang A.M., Salazar A.M., Lamb B.T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement. 2018;4:575–590. doi: 10.1016/j.trci.2018.06.014. PubMed DOI PMC

Forloni G., Balducci C. Alzheimer’s Disease, Oligomers, and Inflammation. J. Alzheimer’s Dis. 2018;62:1261–1276. doi: 10.3233/JAD-170819. PubMed DOI PMC

Chung W.S., Welsh C.A., Barres B.A., Stevens B. Do glia drive synaptic and cognitive impairment in disease? Nat. Neurosci. 2015;18:1539–1545. doi: 10.1038/nn.4142. PubMed DOI PMC

Meraz-Rios M.A., Toral-Rios D., Franco-Bocanegra D., Villeda-Hernandez J., Campos-Pena V. Inflammatory process in Alzheimer’s Disease. Front. Integr. Neurosci. 2013;7:59. doi: 10.3389/fnint.2013.00059. PubMed DOI PMC

Ghosh S., Wu M.D., Shaftel S.S., Kyrkanides S., LaFerla F.M., Olschowka J.A., O’Banion M.K. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J. Neurosci. 2013;33:5053–5064. doi: 10.1523/JNEUROSCI.4361-12.2013. PubMed DOI PMC

Kitazawa M., Cheng D., Tsukamoto M.R., Koike M.A., Wes P.D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model. J. Immunol. 2011;187:6539–6549. doi: 10.4049/jimmunol.1100620. PubMed DOI PMC

Rivers-Auty J., Mather A.E., Peters R., Lawrence C.B., Brough D. Anti-inflammatories in Alzheimer’s disease-potential therapy or spurious correlate? Brain Commun. 2020;2:fcaa109. doi: 10.1093/braincomms/fcaa109. PubMed DOI PMC

Wei Z., Koya J., Reznik S.E. Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Front. Neurosci. 2021;15:687157. doi: 10.3389/fnins.2021.687157. PubMed DOI PMC

Murrow B.A., Hoehn K.L. Mitochondrial regulation of insulin action. Int. J. Biochem. Cell Biol. 2010;42:1936–1939. doi: 10.1016/j.biocel.2010.08.020. PubMed DOI

Clark I.A., Vissel B. Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, alpha-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases. Br. J. Pharmacol. 2018;175:3859–3875. doi: 10.1111/bph.14471. PubMed DOI PMC

Munoz S.S., Garner B., Ooi L. Understanding the Role of ApoE Fragments in Alzheimer’s Disease. Neurochem. Res. 2019;44:1297–1305. doi: 10.1007/s11064-018-2629-1. PubMed DOI

Butterfield D.A., Mattson M.P. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer’s disease. Neurobiol. Dis. 2020;138:104795. doi: 10.1016/j.nbd.2020.104795. PubMed DOI PMC

Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA. 2003;100:10966–10971. doi: 10.1073/pnas.1434398100. PubMed DOI PMC

Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. USA. 2005;102:18694–18699. doi: 10.1073/pnas.0508254102. PubMed DOI PMC

Dafnis I., Tzinia A.K., Tsilibary E.C., Zannis V.I., Chroni A. An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines. Neuroscience. 2012;210:21–32. doi: 10.1016/j.neuroscience.2012.03.013. PubMed DOI PMC

Hohn A., Tramutola A., Cascella R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxid. Med. Cell. Longev. 2020;2020:5497046. doi: 10.1155/2020/5497046. PubMed DOI PMC

Tramutola A., Di Domenico F., Barone E., Perluigi M., Butterfield D.A. It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxid. Med. Cell. Longev. 2016;2016:2756068. doi: 10.1155/2016/2756068. PubMed DOI PMC

Hong L., Huang H.C., Jiang Z.F. Relationship between amyloid-β and the ubiquitin-proteasome system in Alzheimer’s disease. Neurol. Res. 2014;36:276–282. doi: 10.1179/1743132813Y.0000000288. PubMed DOI

Reddy P.H., Oliver D.M. Amyloid β and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease. Cells. 2019;8:488. doi: 10.3390/cells8050488. PubMed DOI PMC

Salminen A., Kaarniranta K., Kauppinen A., Ojala J., Haapasalo A., Soininen H., Hiltunen M. Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1 interactome. Prog. Neurobiol. 2013;106–107:33–54. doi: 10.1016/j.pneurobio.2013.06.002. PubMed DOI

Lee M.J., Lee J.H., Rubinsztein D.C. Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 2013;105:49–59. doi: 10.1016/j.pneurobio.2013.03.001. PubMed DOI

Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006;15:1437–1449. doi: 10.1093/hmg/ddl066. PubMed DOI

Supnet C., Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium. 2010;47:183–189. doi: 10.1016/j.ceca.2009.12.014. PubMed DOI PMC

Jack C.R., Jr., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–128. doi: 10.1016/S1474-4422(09)70299-6. PubMed DOI PMC

Small S.A., Duff K. Linking Aβ and tau in late-onset Alzheimer’s disease: A dual pathway hypothesis. Neuron. 2008;60:534–542. doi: 10.1016/j.neuron.2008.11.007. PubMed DOI PMC

Han P., Shi J. A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer’s Disease. J. Alzheimer’s Dis. 2016;52:1461–1470. doi: 10.3233/JAD-151206. PubMed DOI

Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. USA. 2004;101:284–289. doi: 10.1073/pnas.2635903100. PubMed DOI PMC

Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. USA. 2007;104:19067–19072. doi: 10.1073/pnas.0705036104. PubMed DOI PMC

Jagust W.J., Mormino E.C. Lifespan brain activity, β-amyloid, and Alzheimer’s disease. Trends Cogn. Sci. 2011;15:520–526. doi: 10.1016/j.tics.2011.09.004. PubMed DOI PMC

Kukreja L., Kujoth G.C., Prolla T.A., Van Leuven F., Vassar R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer’s disease. Mol. Neurodegener. 2014;9:16. doi: 10.1186/1750-1326-9-16. PubMed DOI PMC

Goyal S., Chaturvedi R.K. Mitochondrial Protein Import Dysfunction in Pathogenesis of Neurodegenerative Diseases. Mol. Neurobiol. 2021;58:1418–1437. doi: 10.1007/s12035-020-02200-0. PubMed DOI

Fernandez-Vizarra P., Fernandez A.P., Castro-Blanco S., Serrano J., Bentura M.L., Martinez-Murillo R., Martinez A., Rodrigo J. Intra- and extracellular Aβ and PHF in clinically evaluated cases of Alzheimer’s disease. Histol. Histopathol. 2004;19:823–844. doi: 10.14670/HH-19.823. PubMed DOI

Hu W., Wang Z., Zheng H. Mitochondrial accumulation of amyloid β (Aβ) peptides requires TOMM22 as a main Aβ receptor in yeast. J. Biol. Chem. 2018;293:12681–12689. doi: 10.1074/jbc.RA118.002713. PubMed DOI PMC

Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., et al. The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA. 2008;105:13145–13150. doi: 10.1073/pnas.0806192105. PubMed DOI PMC

Kawahara M. Neurotoxicity of β-amyloid protein: Oligomerization, channel formation, and calcium dyshomeostasis. Curr. Pharm. Des. 2010;16:2779–2789. doi: 10.2174/138161210793176545. PubMed DOI

Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304:448–452. doi: 10.1126/science.1091230. PubMed DOI

Takuma K., Yao J., Huang J., Xu H., Chen X., Luddy J., Trillat A.C., Stern D.M., Arancio O., Yan S.S. ABAD enhances Aβ-induced cell stress via mitochondrial dysfunction. FASEB J. 2005;19:597–598. doi: 10.1096/fj.04-2582fje. PubMed DOI

Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 2008;14:1097–1105. doi: 10.1038/nm.1868. PubMed DOI PMC

Bogorodskiy A., Okhrimenko I., Burkatovskii D., Jakobs P., Maslov I., Gordeliy V., Dencher N.A., Gensch T., Voos W., Altschmied J., et al. Role of Mitochondrial Protein Import in Age-Related Neurodegenerative and Cardiovascular Diseases. Cells. 2021;10:3528. doi: 10.3390/cells10123528. PubMed DOI PMC

Mary A., Eysert F., Checler F., Chami M. Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. Mol. Psychiatry. 2022:1–15. doi: 10.1038/s41380-022-01631-6. PubMed DOI PMC

Du H., Yan S.S. Mitochondrial permeability transition pore in Alzheimer’s disease: Cyclophilin D and amyloid β. Biochim. Biophys. Acta. 2010;1802:198–204. doi: 10.1016/j.bbadis.2009.07.005. PubMed DOI PMC

Chaturvedi R.K., Flint Beal M. Mitochondrial diseases of the brain. Free Radic. Biol. Med. 2013;63:1–29. doi: 10.1016/j.freeradbiomed.2013.03.018. PubMed DOI

Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Aβ: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 2005;19:2040–2041. doi: 10.1096/fj.05-3735fje. PubMed DOI

Chen J.X., Yan S.D. Amyloid-β-induced mitochondrial dysfunction. J. Alzheimer’s Dis. 2007;12:177–184. doi: 10.3233/JAD-2007-12208. PubMed DOI PMC

Shearman M.S., Ragan C.I., Iversen L.L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA. 1994;91:1470–1474. doi: 10.1073/pnas.91.4.1470. PubMed DOI PMC

Casley C.S., Canevari L., Land J.M., Clark J.B., Sharpe M.A. Β-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 2002;80:91–100. doi: 10.1046/j.0022-3042.2001.00681.x. PubMed DOI

Moreira P.I., Santos M.S., Moreno A., Rego A.C., Oliveira C. Effect of amyloid β-peptide on permeability transition pore: A comparative study. J. Neurosci. Res. 2002;69:257–267. doi: 10.1002/jnr.10282. PubMed DOI

Tillement L., Lecanu L., Yao W.G., Greeson J., Papadopoulos V. The spirostenol (22R, 25R)-20 alpha-spirost-5-en-3 β-yl hexanoate blocks mitochondrial uptake of Aβ in neuronal cells and prevents Aβ-induced impairment of mitochondrial function. Steroids. 2006;71:725–735. doi: 10.1016/j.steroids.2006.05.003. PubMed DOI

Falkevall A., Alikhani N., Bhushan S., Pavlov P.F., Busch K., Johnson K.A., Eneqvist T., Tjernberg L., Ankarcrona M., Glaser E. Degradation of the amyloid β-protein by the novel mitochondrial peptidasome, PreP. J. Biol. Chem. 2006;281:29096–29104. doi: 10.1074/jbc.M602532200. PubMed DOI

De Strooper B. Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol. Rev. 2010;90:465–494. doi: 10.1152/physrev.00023.2009. PubMed DOI

Manczak M., Reddy P.H. Abnormal interaction of VDAC1 with amyloid β and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum. Mol. Genet. 2012;21:5131–5146. doi: 10.1093/hmg/dds360. PubMed DOI PMC

Atlante A., Valenti D., Latina V., Amadoro G. Dysfunction of Mitochondria in Alzheimer’s Disease: ANT and VDAC Interact with Toxic Proteins and Aid to Determine the Fate of Brain Cells. Int. J. Mol. Sci. 2022;23:7722. doi: 10.3390/ijms23147722. PubMed DOI PMC

Karikari T.K., Nagel D.A., Grainger A., Clarke-Bland C., Hill E.J., Moffat K.G. Preparation of stable tau oligomers for cellular and biochemical studies. Anal. Biochem. 2019;566:67–74. doi: 10.1016/j.ab.2018.10.013. PubMed DOI PMC

Cieri D., Vicario M., Vallese F., D’Orsi B., Berto P., Grinzato A., Catoni C., De Stefani D., Rizzuto R., Brini M., et al. Tau localises within mitochondrial sub-compartments and its caspase cleavage affects ER-mitochondria interactions and cellular Ca2+ handling. Biochim. Biophys. Acta Mol. Basis Dis. 2018;1864:3247–3256. doi: 10.1016/j.bbadis.2018.07.011. PubMed DOI

Shafiei S.S., Guerrero-Munoz M.J., Castillo-Carranza D.L. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front. Aging Neurosci. 2017;9:83. doi: 10.3389/fnagi.2017.00083. PubMed DOI PMC

Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid β with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum. Mol. Genet. 2011;20:2495–2509. doi: 10.1093/hmg/ddr139. PubMed DOI PMC

Manczak M., Reddy P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012;21:2538–2547. doi: 10.1093/hmg/dds072. PubMed DOI PMC

Camilleri A., Ghio S., Caruana M., Weckbecker D., Schmidt F., Kamp F., Leonov A., Ryazanov S., Griesinger C., Giese A., et al. Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochim. Biophys. Acta Biomembr. 2020;1862:183064. doi: 10.1016/j.bbamem.2019.183064. PubMed DOI

Li X.C., Hu Y., Wang Z.H., Luo Y., Zhang Y., Liu X.P., Feng Q., Wang Q., Ye K., Liu G.P., et al. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci. Rep. 2016;6:24756. doi: 10.1038/srep24756. PubMed DOI PMC

Perez M.J., Jara C., Quintanilla R.A. Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration. Front. Neurosci. 2018;12:441. doi: 10.3389/fnins.2018.00441. PubMed DOI PMC

Aleardi A.M., Benard G., Augereau O., Malgat M., Talbot J.C., Mazat J.P., Letellier T., Dachary-Prigent J., Solaini G.C., Rossignol R. Gradual alteration of mitochondrial structure and function by β-amyloids: Importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 2005;37:207–225. doi: 10.1007/s10863-005-6631-3. PubMed DOI

Kaminsky Y.G., Tikhonova L.A., Kosenko E.A. Critical analysis of Alzheimer’s amyloid-β toxicity to mitochondria. Front. Biosci. 2015;20:173–197. doi: 10.2741/4304. PubMed DOI

Pagani L., Eckert A. Amyloid-β interaction with mitochondria. Int. J. Alzheimer’s Dis. 2011;2011:925050. doi: 10.4061/2011/925050. PubMed DOI PMC

Kerr J.S., Adriaanse B.A., Greig N.H., Mattson M.P., Cader M.Z., Bohr V.A., Fang E.F. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 2017;40:151–166. doi: 10.1016/j.tins.2017.01.002. PubMed DOI PMC

Cummings J., Lee G., Nahed P., Kambar M., Zhong K., Fonseca J., Taghva K. Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s Dement. 2022;8:e12295. doi: 10.1002/trc2.12295. PubMed DOI PMC

Athar T., Al Balushi K., Khan S.A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol. Biol. Rep. 2021;48:5629–5645. doi: 10.1007/s11033-021-06512-9. PubMed DOI PMC

Pardo-Moreno T., Gonzalez-Acedo A., Rivas-Dominguez A., Garcia-Morales V., Garcia-Cozar F.J., Ramos-Rodriguez J.J., Melguizo-Rodriguez L. Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives. Pharmaceutics. 2022;14:1117. doi: 10.3390/pharmaceutics14061117. PubMed DOI PMC

Fisar Z., Musilek K., Benek O., Hroch L., Vinklarova L., Schmidt M., Hroudova J., Raboch J. Effects of novel 17β-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration. Toxicol. Lett. 2021;339:12–19. doi: 10.1016/j.toxlet.2020.12.012. PubMed DOI

Pogacnik L., Ota A., Ulrih N.P. An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. Cells. 2020;9:576. doi: 10.3390/cells9030576. PubMed DOI PMC

Thu Thuy Nguyen V., Endres K. Targeting gut microbiota to alleviate neuroinflammation in Alzheimer’s disease. Adv. Drug Deliv. Rev. 2022;188:114418. doi: 10.1016/j.addr.2022.114418. PubMed DOI

Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F., 3rd Serotonin in aging, late-life depression, and Alzheimer’s disease: The emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407–430. doi: 10.1016/S0893-133X(97)00194-2. PubMed DOI

Dringenberg H.C. Alzheimer’s disease: More than a ‘cholinergic disorder’—Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav. Brain Res. 2000;115:235–249. doi: 10.1016/S0166-4328(00)00261-8. PubMed DOI

Guzman-Ramos K., Osorio-Gomez D., Bermudez-Rattoni F. Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis. Neuroscience. 2022;497:308–323. doi: 10.1016/j.neuroscience.2022.05.031. PubMed DOI

Wang W., Karamanlidis G., Tian R. Novel targets for mitochondrial medicine. Sci. Transl. Med. 2016;8:326rv323. doi: 10.1126/scitranslmed.aac7410. PubMed DOI PMC

Fisar Z., Hroudova J. Measurement of Mitochondrial Respiration in Platelets. Methods Mol. Biol. 2021;2277:269–276. doi: 10.1007/978-1-0716-1270-5_16. PubMed DOI

Grimm A., Schmitt K., Eckert A. Advanced Mitochondrial Respiration Assay for Evaluation of Mitochondrial Dysfunction in Alzheimer’s Disease. Methods Mol. Biol. 2016;1303:171–183. doi: 10.1007/978-1-4939-2627-5_9. PubMed DOI

Hroudova J., Fisar Z. Assessment of the Effects of Drugs on Mitochondrial Respiration. Methods Mol. Biol. 2021;2277:133–142. doi: 10.1007/978-1-0716-1270-5_9. PubMed DOI

Singh N., Hroudova J., Fisar Z. In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity. Mol. Neurobiol. 2017;54:5894–5904. doi: 10.1007/s12035-016-0121-y. PubMed DOI

Hroudova J., Novakova T., Korabecny J., Malinak D., Gorecki L., Fisar Z. Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activity—In Vitro Study. Mol. Neurobiol. 2021;58:1102–1113. doi: 10.1007/s12035-020-02172-1. PubMed DOI

Nicoll J.A.R., Buckland G.R., Harrison C.H., Page A., Harris S., Love S., Neal J.W., Holmes C., Boche D. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease. Brain. 2019;142:2113–2126. doi: 10.1093/brain/awz142. PubMed DOI PMC

Morris G.P., Clark I.A., Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol. Commun. 2014;2:135. doi: 10.1186/s40478-014-0135-5. PubMed DOI PMC

Tolar M., Hey J., Power A., Abushakra S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci. 2021;22:6355. doi: 10.3390/ijms22126355. PubMed DOI PMC

Puzzo D., Privitera L., Fa M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M., et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 2011;69:819–830. doi: 10.1002/ana.22313. PubMed DOI PMC

Ghazanfari D., Noori M.S., Bergmeier S.C., Hines J.V., McCall K.D., Goetz D.J. A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism. Bioorg. Med. Chem. 2021;40:116179. doi: 10.1016/j.bmc.2021.116179. PubMed DOI PMC

Wang L., Bharti, Kumar R., Pavlov P.F., Winblad B. Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance. Eur. J. Med. Chem. 2021;209:112915. doi: 10.1016/j.ejmech.2020.112915. PubMed DOI

Medina M. An Overview on the Clinical Development of Tau-Based Therapeutics. Int. J. Mol. Sci. 2018;19:1160. doi: 10.3390/ijms19041160. PubMed DOI PMC

Tolar M., Abushakra S., Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer’s Dement. 2020;16:1553–1560. doi: 10.1016/j.jalz.2019.09.075. PubMed DOI

Sengupta U., Nilson A.N., Kayed R. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine. 2016;6:42–49. doi: 10.1016/j.ebiom.2016.03.035. PubMed DOI PMC

Krafft G.A., Jerecic J., Siemers E., Cline E.N. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease. Front. Neurosci. 2022;16:848215. doi: 10.3389/fnins.2022.848215. PubMed DOI PMC

Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005;26:27–35. doi: 10.1016/j.tips.2004.11.007. PubMed DOI

Hroch L., Guest P., Benek O., Soukup O., Janockova J., Dolezal R., Kuca K., Aitken L., Smith T.K., Gunn-Moore F., et al. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment. Bioorg. Med. Chem. 2017;25:1143–1152. doi: 10.1016/j.bmc.2016.12.029. PubMed DOI

Benek O., Hroch L., Aitken L., Gunn-Moore F., Vinklarova L., Kuca K., Perez D.I., Perez C., Martinez A., Fisar Z., et al. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. J. Enzyme Inhib. Med. Chem. 2018;33:665–670. doi: 10.1080/14756366.2018.1445736. PubMed DOI PMC

Moreira N., Lima J., Marchiori M.F., Carvalho I., Sakamoto-Hojo E.T. Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives. J. Alzheimer’s Dis. Rep. 2022;6:177–193. doi: 10.3233/ADR-210061. PubMed DOI PMC

Sang Z., Wang K., Dong J., Tang L. Alzheimer’s disease: Updated multi-targets therapeutics are in clinical and in progress. Eur. J. Med. Chem. 2022;238:114464. doi: 10.1016/j.ejmech.2022.114464. PubMed DOI

Weinreb O., Mandel S., Bar-Am O., Yogev-Falach M., Avramovich-Tirosh Y., Amit T., Youdim M.B. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics. 2009;6:163–174. doi: 10.1016/j.nurt.2008.10.030. PubMed DOI PMC

Weinstock M., Luques L., Bejar C., Shoham S. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J. Neural Transm. Suppl. 2006:443–446. doi: 10.1007/978-3-211-45295-0_67. PubMed DOI

Haddad H.W., Malone G.W., Comardelle N.J., Degueure A.E., Poliwoda S., Kaye R.J., Murnane K.S., Kaye A.M., Kaye A.D. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review. Health Psychol. Res. 2022;10:37023. doi: 10.52965/001c.37023. PubMed DOI PMC

Vaz M., Silva V., Monteiro C., Silvestre S. Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities. Clin. Interv. Aging. 2022;17:797–810. doi: 10.2147/CIA.S325026. PubMed DOI PMC

Khoury R., Rajamanickam J., Grossberg G.T. An update on the safety of current therapies for Alzheimer’s disease: Focus on rivastigmine. Ther. Adv. Drug Saf. 2018;9:171–178. doi: 10.1177/2042098617750555. PubMed DOI PMC

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006;2006:CD005593. doi: 10.1002/14651858.CD005593. PubMed DOI PMC

McShane R., Westby M.J., Roberts E., Minakaran N., Schneider L., Farrimond L.E., Maayan N., Ware J., Debarros J. Memantine for dementia. Cochrane Database Syst. Rev. 2019;3:CD003154. doi: 10.1002/14651858.CD003154.pub6. PubMed DOI PMC

Dai J., Ports K.D., Corrada M.M., Odegaard A.O., O’Connell J., Jiang L. Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases. J. Alzheimer’s Dis. Rep. 2022;6:443–459. doi: 10.3233/ADR-220002. PubMed DOI PMC

Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi: 10.1007/s00125-017-4342-z. PubMed DOI PMC

Mahapatra M.K., Karuppasamy M., Sahoo B.M. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm. Res. 2022;39:1233–1248. doi: 10.1007/s11095-022-03302-1. PubMed DOI PMC

Henderson S.T., Vogel J.L., Barr L.J., Garvin F., Jones J.J., Costantini L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. 2009;6:31. doi: 10.1186/1743-7075-6-31. PubMed DOI PMC

Croteau E., Castellano C.A., Richard M.A., Fortier M., Nugent S., Lepage M., Duchesne S., Whittingstall K., Turcotte E.E., Bocti C., et al. Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease. J. Alzheimer’s Dis. 2018;64:551–561. doi: 10.3233/JAD-180202. PubMed DOI

Wood A.H.R., Chappell H.F., Zulyniak M.A. Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease. Eur. J. Nutr. 2022;61:589–604. doi: 10.1007/s00394-021-02655-4. PubMed DOI PMC

Bhatt D.L., Hull M.A., Song M., Van Hulle C., Carlsson C., Chapman M.J., Toth P.P. Beyond cardiovascular medicine: Potential future uses of icosapent ethyl. Eur. Heart J. Suppl. 2020;22:J54–J64. doi: 10.1093/eurheartj/suaa119. PubMed DOI PMC

Hampel H., Williams C., Etcheto A., Goodsaid F., Parmentier F., Sallantin J., Kaufmann W.E., Missling C.U., Afshar M. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer’s Dement. 2020;6:e12013. doi: 10.1002/trc2.12013. PubMed DOI PMC

Sanati M., Aminyavari S., Afshari A.R., Sahebkar A. Mechanistic insight into the role of metformin in Alzheimer’s disease. Life Sci. 2022;291:120299. doi: 10.1016/j.lfs.2021.120299. PubMed DOI

Sabbagh M.N., Decourt B. COR388 (atuzaginstat): An investigational gingipain inhibitor for the treatment of Alzheimer disease. Expert Opin. Investig. Drugs. 2022;31:987–993. doi: 10.1080/13543784.2022.2117605. PubMed DOI PMC

Piscopo P., Crestini A., Carbone E., Rivabene R., Ancidoni A., Lo Giudice M., Corbo M., Vanacore N., Lacorte E. A systematic review on drugs for synaptic plasticity in the treatment of dementia. Ageing Res. Rev. 2022;81:101726. doi: 10.1016/j.arr.2022.101726. PubMed DOI

Zheng X.Y., Zhang H.C., Lv Y.D., Jin F.Y., Wu X.J., Zhu J., Ruan Y. Levetiracetam alleviates cognitive decline in Alzheimer’s disease animal model by ameliorating the dysfunction of the neuronal network. Front. Aging Neurosci. 2022;14:888784. doi: 10.3389/fnagi.2022.888784. PubMed DOI PMC

Wang H.Y., Bakshi K., Frankfurt M., Stucky A., Goberdhan M., Shah S.M., Burns L.H. Reducing amyloid-related Alzheimer’s disease pathogenesis by a small molecule targeting filamin A. J. Neurosci. 2012;32:9773–9784. doi: 10.1523/JNEUROSCI.0354-12.2012. PubMed DOI PMC

Tolar M., Abushakra S., Hey J.A., Porsteinsson A., Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimer’s Res. Ther. 2020;12:95. doi: 10.1186/s13195-020-00663-w. PubMed DOI PMC

Abushakra S., Porsteinsson A., Scheltens P., Sadowsky C., Vellas B., Cummings J., Gauthier S., Hey J.A., Power A., Wang P., et al. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential. J. Prev. Alzheimer’s Dis. 2017;4:149–156. doi: 10.14283/jpad.2017.26. PubMed DOI

Reading C.L., Ahlem C.N., Murphy M.F. NM101 Phase III study of NE3107 in Alzheimer’s disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener. Dis. Manag. 2021;11:289–298. doi: 10.2217/nmt-2021-0022. PubMed DOI

Hamaguchi T., Ono K., Yamada M. REVIEW: Curcumin and Alzheimer’s disease. CNS Neurosci. Ther. 2010;16:285–297. doi: 10.1111/j.1755-5949.2010.00147.x. PubMed DOI PMC

Malafaia D., Albuquerque H.M.T., Silva A.M.S. Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. Eur. J. Med. Chem. 2021;214:113209. doi: 10.1016/j.ejmech.2021.113209. PubMed DOI

Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005;280:5892–5901. doi: 10.1074/jbc.M404751200. PubMed DOI

Jakubowski J.M., Orr A.A., Le D.A., Tamamis P. Interactions between Curcumin Derivatives and Amyloid-β Fibrils: Insights from Molecular Dynamics Simulations. J. Chem. Inf. Model. 2020;60:289–305. doi: 10.1021/acs.jcim.9b00561. PubMed DOI PMC

Arndt J.W., Qian F., Smith B.A., Quan C., Kilambi K.P., Bush M.W., Walz T., Pepinsky R.B., Bussiere T., Hamann S., et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep. 2018;8:6412. doi: 10.1038/s41598-018-24501-0. PubMed DOI PMC

Soderberg L., Johannesson M., Nygren P., Laudon H., Eriksson F., Osswald G., Moller C., Lannfelt L. Lecanemab, Aducanumab, and Gantenerumab—Binding Profiles to Different Forms of Amyloid-β Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics. 2022:1–12. doi: 10.1007/s13311-022-01308-6. PubMed DOI PMC

Bouter Y., Liekefeld H., Pichlo S., Westhoff A.C., Fenn L., Bakrania P., Bayer T.A. Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome. Acta Neuropathol. 2022;143:601–603. doi: 10.1007/s00401-022-02418-3. PubMed DOI PMC

Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014;370:311–321. doi: 10.1056/NEJMoa1312889. PubMed DOI

YM M.Y., Waldvogel H.J., Faull R.L.M., Kwakowsky A. Neuroprotective Effect of Caffeine in Alzheimer’s Disease. Molecules. 2022;27:3737. doi: 10.3390/molecules27123737. PubMed DOI PMC

Vaughan R.A., Garcia-Smith R., Bisoffi M., Trujillo K.A., Conn C.A. Effects of caffeine on metabolism and mitochondria biogenesis in rhabdomyosarcoma cells compared with 2,4-dinitrophenol. Nutr. Metab. Insights. 2012;5:59–70. doi: 10.4137/NMI.S10233. PubMed DOI PMC

Hoang K., Watt H., Golemme M., Perry R.J., Ritchie C., Wilson D., Pickett J., Fox C., Howard R., Malhotra P.A. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): Study protocol for a randomised clinical trial and COVID-19 amendments. Trials. 2022;23:623. doi: 10.1186/s13063-022-06190-3. PubMed DOI PMC

Xiao S., Wang T., Ma X., Qin Y., Li X., Zhao Z., Liu X., Wang X., Xie H., Jiang Q., et al. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer’s disease: A Phase II multicenter randomised controlled trial. Age Ageing. 2017;46:767–773. doi: 10.1093/ageing/afx045. PubMed DOI

Rangani R.J., Upadhya M.A., Nakhate K.T., Kokare D.M., Subhedar N.K. Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer’s disease. Peptides. 2012;33:317–328. doi: 10.1016/j.peptides.2012.01.004. PubMed DOI

Mihailescu S., Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch. Med. Res. 2000;31:131–144. doi: 10.1016/S0188-4409(99)00087-9. PubMed DOI

Li L., Xu S., Liu L., Feng R., Gong Y., Zhao X., Li J., Cai J., Feng N., Wang L., et al. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer’s Disease. J. Alzheimer’s Dis. 2017;56:1403–1417. doi: 10.3233/JAD-160587. PubMed DOI

Miziak B., Blaszczyk B., Czuczwar S.J. Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease. Pharmaceuticals. 2021;14:458. doi: 10.3390/ph14050458. PubMed DOI PMC

Grossberg G.T., Kohegyi E., Mergel V., Josiassen M.K., Meulien D., Hobart M., Slomkowski M., Baker R.A., McQuade R.D., Cummings J.L. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am. J. Geriatr. Psychiatry. 2020;28:383–400. doi: 10.1016/j.jagp.2019.09.009. PubMed DOI

Ward K., Citrome L. AXS-05: An investigational treatment for Alzheimer’s disease-associated agitation. Expert Opin. Investig. Drugs. 2022;31:773–780. doi: 10.1080/13543784.2022.2096006. PubMed DOI

Ahmed M., Malik M., Teselink J., Lanctot K.L., Herrmann N. Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs Aging. 2019;36:589–605. doi: 10.1007/s40266-019-00668-7. PubMed DOI

Bosnjak Kuharic D., Markovic D., Brkovic T., Jeric Kegalj M., Rubic Z., Vuica Vukasovic A., Jeroncic A., Puljak L. Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev. 2021;9:CD012820. doi: 10.1002/14651858.CD012820.pub2. PubMed DOI PMC

Ozarowski M., Karpinski T.M., Zielinska A., Souto E.B., Wielgus K. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. Int. J. Mol. Sci. 2021;22:4294. doi: 10.3390/ijms22094294. PubMed DOI PMC

Wang J.H., Wu Y.J., Tee B.L., Lo R.Y. Medical Comorbidity in Alzheimer’s Disease: A Nested Case-Control Study. J. Alzheimer’s Dis. 2018;63:773–781. doi: 10.3233/JAD-170786. PubMed DOI

Eshetie T.C., Nguyen T.A., Gillam M.H., Kalisch Ellett L.M. Medication Use for Comorbidities in People with Alzheimer’s Disease: An Australian Population-Based Study. Pharmacotherapy. 2019;39:1146–1156. doi: 10.1002/phar.2341. PubMed DOI

Majidazar R., Rezazadeh-Gavgani E., Sadigh-Eteghad S., Naseri A. Pharmacotherapy of Alzheimer’s disease: An overview of systematic reviews. Eur. J. Clin. Pharmacol. 2022;78:1567–1587. doi: 10.1007/s00228-022-03363-6. PubMed DOI

Butler M., Nelson V.A., Davila H., Ratner E., Fink H.A., Hemmy L.S., McCarten J.R., Barclay T.R., Brasure M., Kane R.L. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann. Intern. Med. 2018;168:52–62. doi: 10.7326/M17-1530. PubMed DOI

Choi H., Park H.H., Koh S.H., Choi N.Y., Yu H.J., Park J., Lee Y.J., Lee K.Y. Coenzyme Q10 protects against amyloid β-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology. 2012;33:85–90. doi: 10.1016/j.neuro.2011.12.005. PubMed DOI

Paradies G., Paradies V., Ruggiero F.M., Petrosillo G. Mitochondrial bioenergetics decay in aging: Beneficial effect of melatonin. Cell. Mol. Life Sci. 2017;74:3897–3911. doi: 10.1007/s00018-017-2619-5. PubMed DOI PMC

De Castro A.A., Soares F.V., Pereira A.F., Polisel D.A., Caetano M.S., Leal D.H.S., da Cunha E.F.F., Nepovimova E., Kuca K., Ramalho T.C. Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease. Expert Rev. Neurother. 2019;19:375–395. doi: 10.1080/14737175.2019.1608823. PubMed DOI

Lu P.R., Wong S.Y., Wu L., Lin D.B. Carotenoid metabolism in mitochondrial function. Food Qual. Saf. 2020;4:115–122. doi: 10.1093/fqsafe/fyaa023. DOI

Shin S.J., Jeon S.G., Kim J.I., Jeong Y.O., Kim S., Park Y.H., Lee S.K., Park H.H., Hong S.B., Oh S., et al. Red Ginseng Attenuates Aβ-Induced Mitochondrial Dysfunction and Aβ-mediated Pathology in an Animal Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2019;20:3030. doi: 10.3390/ijms20123030. PubMed DOI PMC

Swerdlow R.H. Bioenergetics and metabolism: A bench to bedside perspective. J. Neurochem. 2016;139((Suppl. S2)):126–135. doi: 10.1111/jnc.13509. PubMed DOI PMC

Gauthier S., Feldman H.H., Schneider L.S., Wilcock G.K., Frisoni G.B., Hardlund J.H., Moebius H.J., Bentham P., Kook K.A., Wischik D.J., et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873–2884. doi: 10.1016/S0140-6736(16)31275-2. PubMed DOI PMC

Shin S.J., Park Y.H., Jeon S.G., Kim S., Nam Y., Oh S.M., Lee Y.Y., Moon M. Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro. Oxid. Med. Cell. Longev. 2020;2020:7829842. doi: 10.1155/2020/7829842. PubMed DOI PMC

Chalatsa I., Arvanitis D.A., Koulakiotis N.S., Giagini A., Skaltsounis A.L., Papadopoulou-Daifoti Z., Tsarbopoulos A., Sanoudou D. The Crocus sativus Compounds trans-Crocin 4 and trans-Crocetin Modulate the Amyloidogenic Pathway and Tau Misprocessing in Alzheimer Disease Neuronal Cell Culture Models. Front. Neurosci. 2019;13:249. doi: 10.3389/fnins.2019.00249. PubMed DOI PMC

George R.C., Lew J., Graves D.J. Interaction of cinnamaldehyde and epicatechin with tau: Implications of beneficial effects in modulating Alzheimer’s disease pathogenesis. J. Alzheimer’s Dis. 2013;36:21–40. doi: 10.3233/JAD-122113. PubMed DOI

Viswanathan G.K., Shwartz D., Losev Y., Arad E., Shemesh C., Pichinuk E., Engel H., Raveh A., Jelinek R., Cooper I., et al. Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer’s disease-like symptoms in animal model. Cell. Mol. Life Sci. 2020;77:2795–2813. doi: 10.1007/s00018-019-03312-0. PubMed DOI PMC

Ghasemzadeh S., Riazi G.H. Inhibition of Tau amyloid fibril formation by folic acid: In-vitro and theoretical studies. Int. J. Biol. Macromol. 2020;154:1505–1516. doi: 10.1016/j.ijbiomac.2019.11.032. PubMed DOI

Jia Y., Wang N., Liu X. Resveratrol and Amyloid-β: Mechanistic Insights. Nutrients. 2017;9:1122. doi: 10.3390/nu9101122. PubMed DOI PMC

Yang G., Wang Y., Tian J., Liu J.P. Huperzine A for Alzheimer’s disease: A systematic review and meta-analysis of randomized clinical trials. PLoS ONE. 2013;8:e74916. doi: 10.1371/journal.pone.0074916. PubMed DOI PMC

Xiao X.Q., Wang R., Tang X.C. Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury. J. Neurosci. Res. 2000;61:564–569. doi: 10.1002/1097-4547(20000901)61:5<564::AID-JNR11>3.0.CO;2-X. PubMed DOI

Azizi Z., Majlessi N., Choopani S., Naghdi N. Neuroprotective effects of carvacrol against Alzheimer’s disease and other neurodegenerative diseases: A review. Avicenna J. Phytomed. 2022;12:371–387. doi: 10.22038/AJP.2022.19491. PubMed DOI PMC

Celik Topkara K., Kilinc E., Cetinkaya A., Saylan A., Demir S. Therapeutic effects of carvacrol on β-amyloid-induced impairments in in vitro and in vivo models of Alzheimer’s disease. Eur. J. Neurosci. 2021:1–13. doi: 10.1111/ejn.15565. PubMed DOI

Li Q., Rubin L., Silva M., Li S., Yang C., Lazarovici P., Zheng W. Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease. Oxid. Med. Cell. Longev. 2022;2022:3777021. doi: 10.1155/2022/3777021. PubMed DOI PMC

Shin J.Y., Kang E.S., Park J.H., Cho B.O., Jang S.I. Anti-inflammatory effect of red ginseng marc, Artemisia scoparia, Paeonia japonica and Angelica gigas extract mixture in LPS-stimulated RAW 264.7 cells. Biomed. Rep. 2022;17:63. doi: 10.3892/br.2022.1546. PubMed DOI PMC

Chakraborty B., Mukerjee N., Maitra S., Zehravi M., Mukherjee D., Ghosh A., Massoud E.E.S., Rahman M.H. Therapeutic Potential of Different Natural Products for the Treatment of Alzheimer’s Disease. Oxid. Med. Cell. Longev. 2022;2022:6873874. doi: 10.1155/2022/6873874. PubMed DOI PMC

Aillaud I., Funke S.A. Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease. Cell. Mol. Neurobiol. 2022:1–11. doi: 10.1007/s10571-022-01230-7. PubMed DOI PMC

CoQ10 and Mitochondrial Dysfunction in Alzheimer's Disease

Age-Dependent Alterations in Platelet Mitochondrial Respiration